Influence of Scavenger Receptor Class B Type I (SR-BI) Gene Polymorphisms on Antiviral Treatment Response, and Metabolism in Chronic Hepatitis C Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 309
- 主要终点
- Serum HCV RNA levels
研究概览
简要总结
The scavenger receptor type B class I (SR-BI) is a receptor for high-density lipoproteins (HDL) and one of entry factors for hepatitis C virus (HCV). The investigators aimed to examine the association of single nucleotide polymorphisms (SNPs) of the SCARB1 gene, which encodes SR-BI, with virologic responses to pegylated interferon-based treatment in Asian chronic hepatitis C (CHC) patients.
详细描述
- Purpose of study: To examine the impacts of single nucleotide polymorphisms (SNPs) relevant to SR-BI on CHC patients.
- Study Design To enroll 400 CHC patients during a 3-year period
- Specify objectives of study when collecting extra specimen from participants Collect blood samples for genomic DNA to examine the SR-BI gene polymorphisms.
- Expected Endpoints of Treatment Sustained virologic response (SVR) means undetectable serum HCV RNA levels 24 weeks after completion of antiviral therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Naive to IFN treatment and other experimental antiviral or immunosuppressive therapy before enrollment.
- •Serum alanine aminotransferase levels, at least, twice the upper limit of normal on two occasions within the previous 6 months.
排除标准
- •Positive for hepatitis B surface antigen
- •Positive for human immunodeficiency virus antibody
- •Had a known history or evidence of autoimmune liver disease, inheritable disorders, renal insufficiency, malignancy
- •Had a history of daily alcohol consumption greater than 20 gram or active drug abuse.
研究组 & 干预措施
HCV group (Peginterferon alfa-2a)
A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
干预措施: Peginterferon alfa-2a (Drug)
结局指标
主要结局
Serum HCV RNA levels
时间窗: at 24 weeks after the end of treatment
sustained virologic response
次要结局
- serum fasting blood glucose levels(at 24 weeks after the end of treatment)
研究者
Ching-Sheng Hsu
Attending physician
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation